Cambridge speech recognition business @Speechmatics raises Series A investment from @IQ_Capital_Fund & @AlbionVC to… https://t.co/ff6rERZ8qn
Mon Oct 21 09:15:26View all Tweets >
Scaling in the US: Challenges & Opportunities
Date: 7 November 2019
The latest in our series of Life Sciences Leadership Dinners will explore the challenges and opportunities facing businesses when scaling in the US. We are pleased to announce as our expert guests, Nigel Pitchford, Kym Denny & Paul Kinnon.
Nigel Pitchford is CEO of Ieso Digital Health, a role he took on earlier this year, having previously been a successful life sciences investor at 3i, Draper Esprit and Touchstone Innovations, where he was also Chief Investment Officer. Throughout his career Nigel has been directly exposed to many US entry strategies for UK based companies – some successful, some less so – for businesses such as Apatech, Oxford Immunotec, Horizon Discovery, Abzena and Ieso. He has also been involved with US companies looking to build a presence in their own domestic market.
Kym Denny is former CEO of hVIVO Plc, a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious disease. During her tenure, Kym led one of the most successful IPOs on AIM; developed FLU-V, a first in class universal flu vaccine candidate in partnership with the biotech company SEEK; and set up sales teams in the US. Previously, Kym held senior management and board positions in international clinical trials companies, specialising in growth management and market adoption of new technologies and methodologies to improve the drug development process. Kym was the Ernst & Young UK Life Sciences Entrepreneur of the Year in 2016, and the recipient of the Gold Stevie Award for Female Executive of the Year EMEA. Kym is a US national, and during the early part of her career ran a successful start-up in the States.
Paul Kinnon has over 25 years’ experience in the global life sciences industry, with the past 15 years of his executive career focused on Clinical Diagnostics. He has held leadership positions with Transgenomic (NASDAQ listed), ZyGEM Corp., Life Technologies (now ThermoFisher), Guava Technologies and Cellomics, generating more than $60m in funding, creating global partnerships and increasing shareholder return. Paul has a proven strategic and commercialisation track record, in addition to 10+ years’ international board experience in both private and public companies, with significant expertise in corporate governance, corporate restructuring, M&A and divestiture activities. Paul has spent 20 years of his career in the US and recently established an entity there for PredictImmune, based out of Babraham.
This event is hosted by Bailey Fisher in partnership with Silicon Valley Bank and Penningtons Manches Cooper.
Attendance at this dinner is by invitation for C-suite executives from high-growth Life Sciences businesses. If you are interested in finding out more about this or future events, please contact Iain Hopper or Kerry Linsey.